FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2593820339> ?p ?o ?g. }

• W2593820339 abstract "Cancer treatment with combination of radiotherapy (RT) and immunotherapy (IT) (immune check-point inhibitors) has gained promising results in preclinical and clinical studies. Accumulating evidence suggests that RT is beneficial not only because of its direct cytocidal effect but it also acts as an immunogenic hub, turning the irradiated tumor into an in situ cancer vaccine. In around 25% of patients such combined treatment results not only in shrinkage of the irradiated tumor but also in shrinkage of distant metastases (abscopal effect). However, little is known about the optimal RT dose and fractionation scheme, scheduling of IT and about which patients are candidates for responders. The results of preclinical and clinical studies addressing those questions are sparse and often contradictory. To help understanding the mechanisms of such therapy, we developed a computational model capable of simulating tumor response to treatment with RT and anti-programmed death 1 (anti-PD-1) antibodies. The model describes interplay between tumor cells and cytotoxic T lymphocytes (CTLs) with a set of ordinary differential equations. It incorporates intrinsic tumor and CTLs characteristics, such as radiosensitivity coefficients, PD-1 expression on CTLs, PD-1 ligand (PD-L1) expression on tumor cells, RT dose-dependent major histocompatibility complex class I (MHC-I) expression on tumor cells, etc. Additionally, we incorporated RT dose-dependent increase of damage-associated molecular patterns that play a crucial role in immunogenic cell death, such as calreticulin, ATP and high mobility group box 1. Finally, we studied pharmacokinetic and pharmacodynamic properties of a novel anti-PD-1 antibody and included it in our model. With tuning of some free parameters we successfully reproduced experimental results from literature (mice tumor model), where tumor response to 3 different therapies (anti-PD-1, stereotactic ablative radiotherapy (SABR) 1 x 15 Gy, SABR + anti-PD-1) was studied. The focus of our simulations was on primary irradiated tumor. Once we confirmed ability of the model to reproduce experimental results, we performed a sensitivity analysis of free parameters and studied their impact on tumor response. First we analyzed the impact of MHC-I and PD-L1 expression on tumor response to combined therapy. If the fraction of tumor cells expressing MHC-I is low, the therapy with anti-PD-1 has poor effect on tumor regardless of the fraction of tumor cells expressing PD-L1. SABR, as well as SABR + anti-PD-1, result in a temporary delay of tumor growth but the tumor volume is similar to the untreated tumor 2 weeks after irradiation. Secondly, if the fraction of tumor cells expressing MHC-I is high (fixed in this set of simulations) and the fraction of tumor cells expressing PD-L1 is low, even the untreated tumor does not form. If PD-L1 expression is moderate, the untreated tumor does form, whereas all three therapies result in a complete tumor eradication. If PD-L1 expression is high, SABR, as well as anti-PD-1 alone, result only in a delay of tumor growth. On the other hand, SABR + anti-PD-1 therapy results in a great tumor control even if all tumor cells express PD-L1. Finally, we simulated the combination of anti-PD-1 and different RT regimens (1 × 15 Gy, 3 × 5 Gy, 5 × 3 Gy, 7 x 2.14 Gy) for the case of poorly immunogenic tumor cells (low MHC-I, high PD-L1). In our simulations all three fractionation regimens outperform SABR, resulting in a 50% smaller tumor volume 3 weeks after irradiation. To conclude, we showed that the model of combined cancer therapy was able to reproduce preclinical results (mice tumor model). According to our model, MHC-I expression might play an important role in treatment with anti-PD-1 + RT and deserves further attention. Finally, the model predicts that fractionation should outperform SABR when combining RT with anti-PD-1. Citation Format: Damijan Valentinuzzi, Katja Ursic, Martina Vrankar, Urban Simoncic, Urban Simoncic, Robert Jeraj. Computational model of combined cancer treatment with radiotherapy and anti-PD-1 immunotherapy. [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology and Immunotherapy; 2016 Oct 20-23; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2017;5(3 Suppl):Abstract nr B73." @default.
• W2593820339 created "2017-03-16" @default.
• W2593820339 creator A5030203098 @default.
• W2593820339 creator A5039246968 @default.
• W2593820339 creator A5053514233 @default.
• W2593820339 creator A5054556702 @default.
• W2593820339 creator A5086366456 @default.
• W2593820339 date "2017-02-28" @default.
• W2593820339 modified "2023-09-27" @default.
• W2593820339 title "Abstract B73: Computational model of combined cancer treatment with radiotherapy and anti-PD-1 immunotherapy" @default.
• W2593820339 doi "https://doi.org/10.1158/2326-6074.tumimm16-b73" @default.
• W2593820339 hasPublicationYear "2017" @default.
• W2593820339 type Work @default.
• W2593820339 sameAs 2593820339 @default.
• W2593820339 citedByCount "0" @default.
• W2593820339 crossrefType "proceedings-article" @default.
• W2593820339 hasAuthorship W2593820339A5030203098 @default.
• W2593820339 hasAuthorship W2593820339A5039246968 @default.
• W2593820339 hasAuthorship W2593820339A5053514233 @default.
• W2593820339 hasAuthorship W2593820339A5054556702 @default.
• W2593820339 hasAuthorship W2593820339A5086366456 @default.
• W2593820339 hasConcept C121608353 @default.
• W2593820339 hasConcept C126322002 @default.
• W2593820339 hasConcept C143998085 @default.
• W2593820339 hasConcept C154317977 @default.
• W2593820339 hasConcept C170627219 @default.
• W2593820339 hasConcept C202751555 @default.
• W2593820339 hasConcept C203014093 @default.
• W2593820339 hasConcept C207936829 @default.
• W2593820339 hasConcept C2777701055 @default.
• W2593820339 hasConcept C2777877232 @default.
• W2593820339 hasConcept C2780674031 @default.
• W2593820339 hasConcept C2781274730 @default.
• W2593820339 hasConcept C502942594 @default.
• W2593820339 hasConcept C509974204 @default.
• W2593820339 hasConcept C55493867 @default.
• W2593820339 hasConcept C71924100 @default.
• W2593820339 hasConcept C86803240 @default.
• W2593820339 hasConcept C8891405 @default.
• W2593820339 hasConceptScore W2593820339C121608353 @default.
• W2593820339 hasConceptScore W2593820339C126322002 @default.
• W2593820339 hasConceptScore W2593820339C143998085 @default.
• W2593820339 hasConceptScore W2593820339C154317977 @default.
• W2593820339 hasConceptScore W2593820339C170627219 @default.
• W2593820339 hasConceptScore W2593820339C202751555 @default.
• W2593820339 hasConceptScore W2593820339C203014093 @default.
• W2593820339 hasConceptScore W2593820339C207936829 @default.
• W2593820339 hasConceptScore W2593820339C2777701055 @default.
• W2593820339 hasConceptScore W2593820339C2777877232 @default.
• W2593820339 hasConceptScore W2593820339C2780674031 @default.
• W2593820339 hasConceptScore W2593820339C2781274730 @default.
• W2593820339 hasConceptScore W2593820339C502942594 @default.
• W2593820339 hasConceptScore W2593820339C509974204 @default.
• W2593820339 hasConceptScore W2593820339C55493867 @default.
• W2593820339 hasConceptScore W2593820339C71924100 @default.
• W2593820339 hasConceptScore W2593820339C86803240 @default.
• W2593820339 hasConceptScore W2593820339C8891405 @default.
• W2593820339 hasLocation W25938203391 @default.
• W2593820339 hasOpenAccess W2593820339 @default.
• W2593820339 hasPrimaryLocation W25938203391 @default.
• W2593820339 hasRelatedWork W2347131556 @default.
• W2593820339 hasRelatedWork W2566833162 @default.
• W2593820339 hasRelatedWork W2589863354 @default.
• W2593820339 hasRelatedWork W2762667176 @default.
• W2593820339 hasRelatedWork W2809064179 @default.
• W2593820339 hasRelatedWork W287605918 @default.
• W2593820339 hasRelatedWork W2886213129 @default.
• W2593820339 hasRelatedWork W2891074011 @default.
• W2593820339 hasRelatedWork W2895515586 @default.
• W2593820339 hasRelatedWork W2901755476 @default.
• W2593820339 hasRelatedWork W2952902275 @default.
• W2593820339 hasRelatedWork W2954194535 @default.
• W2593820339 hasRelatedWork W2980394375 @default.
• W2593820339 hasRelatedWork W3037252669 @default.
• W2593820339 hasRelatedWork W3043652864 @default.
• W2593820339 hasRelatedWork W3096739463 @default.
• W2593820339 hasRelatedWork W3111260583 @default.
• W2593820339 hasRelatedWork W3131039777 @default.
• W2593820339 hasRelatedWork W3132467920 @default.
• W2593820339 hasRelatedWork W3208807455 @default.
• W2593820339 isParatext "false" @default.
• W2593820339 isRetracted "false" @default.
• W2593820339 magId "2593820339" @default.
• W2593820339 workType "article" @default.